MRI results in tuberous sclerosis complex before and after treatment

Brain MRI abnormalities in tuberous sclerosis complex before and after treatment

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180928041159N2

Enrollment

Registered

2020-01-26

Start date

2020-01-30

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain MRI abnormalities in tuberous sclerosis complex. Tuberous sclerosis

Interventions

Intervention 1: Intervention group: Everolimus drug in the form of 2.5, 5, 7.5 and 10 mg tablets licensed by Swiss company Novartis which will be prescribed for 6 months after diagnosis. The dose of t

Eligibility

Sex/Gender

All

Age

2 Years to No maximum

Inclusion criteria

Inclusion criteria: Definite diagnosis of tuberous sclerosis complex Age over 2 years Stable hemodynamic conditions Consult to participate in the study

Exclusion criteria

Exclusion criteria: incidence of drug reactions Restriction on the use of Everolimus Cancer Infectious diseases Concurrent use of immunosuppressive drugs

Design outcomes

Primary

Measure	Time frame
Volume changes in giant astrocytoma. Timepoint: At baseline, 6 months after receiving everolimus. Method of measurement: Magnetic Resonance Imaging.;Decrease in the volume of subependymal nodules. Timepoint: At baseline, 6 months after receiving everolimus. Method of measurement: Magnetic Resonance Imaging.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Leyla Yousefi Halvaie

Tabriz University of Medical Sciences

liyousefi511@gmail.com+98 41 3337 6923

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026